# A Clinical Trial Evaluating SCB-219M in in Chemotherapy-induced Thrombocytopenia (CIT)

> **NCT05426369** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Sichuan Clover Biopharmaceuticals, Inc.** · enrollment: 36 (actual)

## Conditions studied

- Chemotherapy-induced Thrombocytopenia (CIT)

## Interventions

- **BIOLOGICAL:** Recombinant Human Tumor Necrosis Factor Receptor II -Fc-TPO Mimetic Peptide Fusion Protein

## Key facts

- **NCT ID:** NCT05426369
- **Lead sponsor:** Sichuan Clover Biopharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-06-14
- **Primary completion:** 2025-07-02
- **Final completion:** 2025-12
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2025-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05426369

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05426369, "A Clinical Trial Evaluating SCB-219M in in Chemotherapy-induced Thrombocytopenia (CIT)". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT05426369. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*